Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment for patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL). One notable complication is immune effector cell-associated neurotoxicity syndrome (ICANS) which can be life-threatening. Treatment includes supportive...
Vivek G. Patel, Shakthi T. Bhaskar, S. Schuster et al.· Transplantation and Cellular...· 0 citations
Outcomes after CAR-T failure in LBCL remain poor despite the availability of multiple salvage treatment strategies, and time to relapse after CAR-T therapy was the strongest prognostic factor.
Smith Kungwankiattichai, Sanjog Bastola, Manoj Rai et al.· Transplantation and Cellular...· 0 citations
The results demonstrate the importance of continuous patient monitoring and management during CAR-T therapy and demonstrate an evolving treatment landscape, including more aggressive management of CRS and interest in preventive therapies for CRS and ICANS.
M. Frigault, R. Maziarz, T. Amoloja et al.· Transplantation and Cellular...· 0 citations
The key challenges inherent to CGT expansion are summarized, priority areas for coordinated action are identified, and a call to the field to address these needs with urgency and shared commitment is issued.
Jeffery J. Auletta, Á. Urbano-Ispizua, R. Maziarz et al.· Transplantation and Cellular...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.